Corporate Overview
Mission
Our mission is to develop cutting-edge therapies that improve patient outcomes and bring hope in the fight against cancer.
Mission
Our mission is to develop cutting-edge therapies that improve patient outcomes and bring hope in the fight against cancer.
Mission
Our mission is to develop cutting-edge therapies that improve patient outcomes and bring hope in the fight against cancer.
Mission
Our mission is to develop cutting-edge therapies that improve patient outcomes and bring hope in the fight against cancer.
Our Position
Onco-Innovations is a leader in cancer research, dedicated to advancing oncology treatments. With an exclusive global license for patented technology targeting solid tumors, we set new benchmarks in cancer care.
Our Position
Onco-Innovations is a leader in cancer research, dedicated to advancing oncology treatments. With an exclusive global license for patented technology targeting solid tumors, we set new benchmarks in cancer care.
Our Position
Onco-Innovations is a leader in cancer research, dedicated to advancing oncology treatments. With an exclusive global license for patented technology targeting solid tumors, we set new benchmarks in cancer care.
Our Position
Onco-Innovations is a leader in cancer research, dedicated to advancing oncology treatments. With an exclusive global license for patented technology targeting solid tumors, we set new benchmarks in cancer care.
World-Class Leadership Team
World-Class Leadership Team
Experienced leadership across healthcare, biotech, and finance, with a proven track record in strategy, innovation, and growth.
Experienced leadership across healthcare, biotech, and finance, with a proven track record in strategy, innovation, and growth.
Management
Management
Management
Thomas O'Shaughnessy
CEO
Mr. O’Shaughnessy, MSc (Oxford), brings 25 years of expertise in healthcare strategy, policy, and operations. As a former Partner at Deloitte Canada, he led health industry growth nationally and spearheaded digital health initiatives. He is the Founder of Carnarvon Strategies and a Senior Advisor for Health Care and Life Sciences at Navigator Ltd., focusing on value creation and strategic execution in the sector.
Thomas O'Shaughnessy
CEO
Mr. O’Shaughnessy, MSc (Oxford), brings 25 years of expertise in healthcare strategy, policy, and operations. As a former Partner at Deloitte Canada, he led health industry growth nationally and spearheaded digital health initiatives. He is the Founder of Carnarvon Strategies and a Senior Advisor for Health Care and Life Sciences at Navigator Ltd., focusing on value creation and strategic execution in the sector.
Thomas O'Shaughnessy
CEO
Mr. O’Shaughnessy, MSc (Oxford), brings 25 years of expertise in healthcare strategy, policy, and operations. As a former Partner at Deloitte Canada, he led health industry growth nationally and spearheaded digital health initiatives. He is the Founder of Carnarvon Strategies and a Senior Advisor for Health Care and Life Sciences at Navigator Ltd., focusing on value creation and strategic execution in the sector.
Thomas O'Shaughnessy
CEO
Mr. O’Shaughnessy, MSc (Oxford), brings 25 years of expertise in healthcare strategy, policy, and operations. As a former Partner at Deloitte Canada, he led health industry growth nationally and spearheaded digital health initiatives. He is the Founder of Carnarvon Strategies and a Senior Advisor for Health Care and Life Sciences at Navigator Ltd., focusing on value creation and strategic execution in the sector.
Nico Mah
CFO & Corporate Secretary
Mr. Mah is a Chartered Professional Accountant and has nearly eight years of experience in auditing and public accountancy, having been an associate and subsequently a manager at PricewaterhouseCoopers LLP, the global audit and assurance, tax, deals and consulting firm from September 2015 to January 2023.
Nico Mah
CFO & Corporate Secretary
Mr. Mah is a Chartered Professional Accountant and has nearly eight years of experience in auditing and public accountancy, having been an associate and subsequently a manager at PricewaterhouseCoopers LLP, the global audit and assurance, tax, deals and consulting firm from September 2015 to January 2023.
Nico Mah
CFO & Corporate Secretary
Mr. Mah is a Chartered Professional Accountant and has nearly eight years of experience in auditing and public accountancy, having been an associate and subsequently a manager at PricewaterhouseCoopers LLP, the global audit and assurance, tax, deals and consulting firm from September 2015 to January 2023.
Nico Mah
CFO & Corporate Secretary
Mr. Mah is a Chartered Professional Accountant and has nearly eight years of experience in auditing and public accountancy, having been an associate and subsequently a manager at PricewaterhouseCoopers LLP, the global audit and assurance, tax, deals and consulting firm from September 2015 to January 2023.
Board of Directors
Board of Directors
Board of Directors
Dr. Richard Heinzl
Director
Dr. Heinzl is the Founder of Doctors Without Borders Canada and a recipient of the Nobel Peace Prize (1999). He is currently the CEO of My Next Health Inc., a company pioneering functional genomics. Previously, he served as Global Medical Director at WorldCare, a Harvard-affiliated virtual medicine company. He holds degrees from McMaster, Harvard, and Oxford, and brings global expertise in genomics and healthcare innovation.
Dr. Richard Heinzl
Director
Dr. Heinzl is the Founder of Doctors Without Borders Canada and a recipient of the Nobel Peace Prize (1999). He is currently the CEO of My Next Health Inc., a company pioneering functional genomics. Previously, he served as Global Medical Director at WorldCare, a Harvard-affiliated virtual medicine company. He holds degrees from McMaster, Harvard, and Oxford, and brings global expertise in genomics and healthcare innovation.
Dr. Richard Heinzl
Director
Dr. Heinzl is the Founder of Doctors Without Borders Canada and a recipient of the Nobel Peace Prize (1999). He is currently the CEO of My Next Health Inc., a company pioneering functional genomics. Previously, he served as Global Medical Director at WorldCare, a Harvard-affiliated virtual medicine company. He holds degrees from McMaster, Harvard, and Oxford, and brings global expertise in genomics and healthcare innovation.
Dr. Richard Heinzl
Director
Dr. Heinzl is the Founder of Doctors Without Borders Canada and a recipient of the Nobel Peace Prize (1999). He is currently the CEO of My Next Health Inc., a company pioneering functional genomics. Previously, he served as Global Medical Director at WorldCare, a Harvard-affiliated virtual medicine company. He holds degrees from McMaster, Harvard, and Oxford, and brings global expertise in genomics and healthcare innovation.
Zachary Stadnyk
Director
Mr. Stadnyk is a distinguished public company executive with over fifteen years of experience leading multi-million-dollar initiatives across Healthcare, Wellness, Technology, Cannabis, and Private Equity sectors. Mr. Stadnyk is the chairman and a director of Right Season Investments Corp., a venture capital, investment and advisory firm listed on the TSXV, since June 2024. Mr. Stadnyk recently led the Life Sciences and Innovation sectors at the TMX Group. Mr. Stadnyk is also the CFO of Redwood AI Inc.
Zachary Stadnyk
Director
Mr. Stadnyk is a distinguished public company executive with over fifteen years of experience leading multi-million-dollar initiatives across Healthcare, Wellness, Technology, Cannabis, and Private Equity sectors. Mr. Stadnyk is the chairman and a director of Right Season Investments Corp., a venture capital, investment and advisory firm listed on the TSXV, since June 2024. Mr. Stadnyk recently led the Life Sciences and Innovation sectors at the TMX Group. Mr. Stadnyk is also the CFO of Redwood AI Inc.
Zachary Stadnyk
Director
Mr. Stadnyk is a distinguished public company executive with over fifteen years of experience leading multi-million-dollar initiatives across Healthcare, Wellness, Technology, Cannabis, and Private Equity sectors. Mr. Stadnyk is the chairman and a director of Right Season Investments Corp., a venture capital, investment and advisory firm listed on the TSXV, since June 2024. Mr. Stadnyk recently led the Life Sciences and Innovation sectors at the TMX Group. Mr. Stadnyk is also the CFO of Redwood AI Inc.
Zachary Stadnyk
Director
Mr. Stadnyk is a distinguished public company executive with over fifteen years of experience leading multi-million-dollar initiatives across Healthcare, Wellness, Technology, Cannabis, and Private Equity sectors. Mr. Stadnyk is the chairman and a director of Right Season Investments Corp., a venture capital, investment and advisory firm listed on the TSXV, since June 2024. Mr. Stadnyk recently led the Life Sciences and Innovation sectors at the TMX Group. Mr. Stadnyk is also the CFO of Redwood AI Inc.
Graydon Bensler
Director
Mr. Bensler is a financial professional and analyst with seven years of experience in financial consulting and management for both private businesses and US/Canadian publicly traded companies and is a Chartered Financial Analyst (CFA). He currently serves as the CEO of Elevai Labs, a publicly listed company on the NASDAQ Exchange.
Graydon Bensler
Director
Mr. Bensler is a financial professional and analyst with seven years of experience in financial consulting and management for both private businesses and US/Canadian publicly traded companies and is a Chartered Financial Analyst (CFA). He currently serves as the CEO of Elevai Labs, a publicly listed company on the NASDAQ Exchange.
Graydon Bensler
Director
Mr. Bensler is a financial professional and analyst with seven years of experience in financial consulting and management for both private businesses and US/Canadian publicly traded companies and is a Chartered Financial Analyst (CFA). He currently serves as the CEO of Elevai Labs, a publicly listed company on the NASDAQ Exchange.
Graydon Bensler
Director
Mr. Bensler is a financial professional and analyst with seven years of experience in financial consulting and management for both private businesses and US/Canadian publicly traded companies and is a Chartered Financial Analyst (CFA). He currently serves as the CEO of Elevai Labs, a publicly listed company on the NASDAQ Exchange.
Maximilian Justus
Director
Mr. Justus is a public company executive with experience in the fashion and apparel industry. Mr. Justus has served as the Chief Executive Officer and Director of Grounded People Apparel since 2020, where he has been focused on driving strategic initiatives, overseeing operations, and expanding market share.
Maximilian Justus
Director
Mr. Justus is a public company executive with experience in the fashion and apparel industry. Mr. Justus has served as the Chief Executive Officer and Director of Grounded People Apparel since 2020, where he has been focused on driving strategic initiatives, overseeing operations, and expanding market share.
Maximilian Justus
Director
Mr. Justus is a public company executive with experience in the fashion and apparel industry. Mr. Justus has served as the Chief Executive Officer and Director of Grounded People Apparel since 2020, where he has been focused on driving strategic initiatives, overseeing operations, and expanding market share.
Maximilian Justus
Director
Mr. Justus is a public company executive with experience in the fashion and apparel industry. Mr. Justus has served as the Chief Executive Officer and Director of Grounded People Apparel since 2020, where he has been focused on driving strategic initiatives, overseeing operations, and expanding market share.
Scientific & Clinical Advisory Board
Scientific & Clinical Advisory Board
Our Scientific and Clinical Advisory Board provides unparalleled expertise in oncology, precision medicine, AI, and drug development.
Our Scientific and Clinical Advisory Board provides unparalleled expertise in oncology, precision medicine, AI, and drug development.
Our Scientific and Clinical Advisory Board provides unparalleled expertise in oncology, precision medicine, AI, and drug development.
Dr. Michael Weinfeld
Dr. Weinfeld, Professor of Oncology at the University of Alberta and Senior Scientist at Alberta Health Services, brings over 40 years of expertise in cancer research. Based at the Cross Cancer Institute, his groundbreaking work focuses on DNA damage and repair, advancing therapies to make cancer cells more vulnerable to radiotherapy and chemotherapy.
Dr. Michael Weinfeld
Dr. Weinfeld, Professor of Oncology at the University of Alberta and Senior Scientist at Alberta Health Services, brings over 40 years of expertise in cancer research. Based at the Cross Cancer Institute, his groundbreaking work focuses on DNA damage and repair, advancing therapies to make cancer cells more vulnerable to radiotherapy and chemotherapy.
Dr. Michael Weinfeld
Dr. Weinfeld, Professor of Oncology at the University of Alberta and Senior Scientist at Alberta Health Services, brings over 40 years of expertise in cancer research. Based at the Cross Cancer Institute, his groundbreaking work focuses on DNA damage and repair, advancing therapies to make cancer cells more vulnerable to radiotherapy and chemotherapy.
Dr. Michael Weinfeld
Dr. Weinfeld, Professor of Oncology at the University of Alberta and Senior Scientist at Alberta Health Services, brings over 40 years of expertise in cancer research. Based at the Cross Cancer Institute, his groundbreaking work focuses on DNA damage and repair, advancing therapies to make cancer cells more vulnerable to radiotherapy and chemotherapy.
Dr. John Mackey
Dr. Mackey, Professor Emeritus in Oncology at the University of Alberta, is a leader in cancer clinical trials, drug development, and novel diagnostics. He co-founded Pacylex Pharmaceuticals, advancing first-in-class anticancer therapies, and leads illumiSonics, pioneering real-time molecular histology. With over 300 publications, 12 patents, and innovations in clinical trial analytics, he was inducted as a Fellow of the Canadian Academy of Health Sciences.
Dr. John Mackey
Dr. Mackey, Professor Emeritus in Oncology at the University of Alberta, is a leader in cancer clinical trials, drug development, and novel diagnostics. He co-founded Pacylex Pharmaceuticals, advancing first-in-class anticancer therapies, and leads illumiSonics, pioneering real-time molecular histology. With over 300 publications, 12 patents, and innovations in clinical trial analytics, he was inducted as a Fellow of the Canadian Academy of Health Sciences.
Dr. John Mackey
Dr. Mackey, Professor Emeritus in Oncology at the University of Alberta, is a leader in cancer clinical trials, drug development, and novel diagnostics. He co-founded Pacylex Pharmaceuticals, advancing first-in-class anticancer therapies, and leads illumiSonics, pioneering real-time molecular histology. With over 300 publications, 12 patents, and innovations in clinical trial analytics, he was inducted as a Fellow of the Canadian Academy of Health Sciences.
Dr. John Mackey
Dr. Mackey, Professor Emeritus in Oncology at the University of Alberta, is a leader in cancer clinical trials, drug development, and novel diagnostics. He co-founded Pacylex Pharmaceuticals, advancing first-in-class anticancer therapies, and leads illumiSonics, pioneering real-time molecular histology. With over 300 publications, 12 patents, and innovations in clinical trial analytics, he was inducted as a Fellow of the Canadian Academy of Health Sciences.
Dr. Frederick West
Dr. West, Allard Research Chair in Oncology at the University of Alberta, specializes in chemical synthesis and structural modification of organic molecules. A key contributor to developing DNA repair inhibitors, his innovative work enhances the efficacy of chemotherapy and radiotherapy in cancer treatment.
Dr. Frederick West
Dr. West, Allard Research Chair in Oncology at the University of Alberta, specializes in chemical synthesis and structural modification of organic molecules. A key contributor to developing DNA repair inhibitors, his innovative work enhances the efficacy of chemotherapy and radiotherapy in cancer treatment.
Dr. Frederick West
Dr. West, Allard Research Chair in Oncology at the University of Alberta, specializes in chemical synthesis and structural modification of organic molecules. A key contributor to developing DNA repair inhibitors, his innovative work enhances the efficacy of chemotherapy and radiotherapy in cancer treatment.
Dr. Frederick West
Dr. West, Allard Research Chair in Oncology at the University of Alberta, specializes in chemical synthesis and structural modification of organic molecules. A key contributor to developing DNA repair inhibitors, his innovative work enhances the efficacy of chemotherapy and radiotherapy in cancer treatment.
Dr. Afsaneh Lavasanifar
Dr. Lavasanifar, Professor in Pharmaceutics at the University of Alberta, is a global leader in polymer-based drug delivery systems, focusing on nano-carriers for cancer immunotherapy and anti-inflammatory treatments. With over 170 publications, 10 patents, and prestigious awards, she also serves as Scientific Chief Officer at Merores Polymers Inc, advancing innovative therapeutics from her lab’s technology.
Dr. Afsaneh Lavasanifar
Dr. Lavasanifar, Professor in Pharmaceutics at the University of Alberta, is a global leader in polymer-based drug delivery systems, focusing on nano-carriers for cancer immunotherapy and anti-inflammatory treatments. With over 170 publications, 10 patents, and prestigious awards, she also serves as Scientific Chief Officer at Merores Polymers Inc, advancing innovative therapeutics from her lab’s technology.
Dr. Afsaneh Lavasanifar
Dr. Lavasanifar, Professor in Pharmaceutics at the University of Alberta, is a global leader in polymer-based drug delivery systems, focusing on nano-carriers for cancer immunotherapy and anti-inflammatory treatments. With over 170 publications, 10 patents, and prestigious awards, she also serves as Scientific Chief Officer at Merores Polymers Inc, advancing innovative therapeutics from her lab’s technology.
Dr. Afsaneh Lavasanifar
Dr. Lavasanifar, Professor in Pharmaceutics at the University of Alberta, is a global leader in polymer-based drug delivery systems, focusing on nano-carriers for cancer immunotherapy and anti-inflammatory treatments. With over 170 publications, 10 patents, and prestigious awards, she also serves as Scientific Chief Officer at Merores Polymers Inc, advancing innovative therapeutics from her lab’s technology.
Dr. Islam Mohamed (Chair)
Dr. Islam Mohamed (Chair), an Honours BSc graduate in Genetics, became a Radiation Oncologist in 2000. At BC Cancer, he has specialized in lung, breast, skin cancers, and sarcoma, with expertise in stereotactic radiation. As a clinical investigator, he has contributed to research, ethics boards, and cancer trial committees. His expertise in cancer genomics, radiobiology, and medical physics now informs his role as an investor and advisor in Canadian biotech firms, including Linax Technologies, IllumiSonics, Asep Medical, and Onco-Innovations.
Dr. Islam Mohamed (Chair)
Dr. Islam Mohamed (Chair), an Honours BSc graduate in Genetics, became a Radiation Oncologist in 2000. At BC Cancer, he has specialized in lung, breast, skin cancers, and sarcoma, with expertise in stereotactic radiation. As a clinical investigator, he has contributed to research, ethics boards, and cancer trial committees. His expertise in cancer genomics, radiobiology, and medical physics now informs his role as an investor and advisor in Canadian biotech firms, including Linax Technologies, IllumiSonics, Asep Medical, and Onco-Innovations.
Dr. Islam Mohamed (Chair)
Dr. Islam Mohamed (Chair), an Honours BSc graduate in Genetics, became a Radiation Oncologist in 2000. At BC Cancer, he has specialized in lung, breast, skin cancers, and sarcoma, with expertise in stereotactic radiation. As a clinical investigator, he has contributed to research, ethics boards, and cancer trial committees. His expertise in cancer genomics, radiobiology, and medical physics now informs his role as an investor and advisor in Canadian biotech firms, including Linax Technologies, IllumiSonics, Asep Medical, and Onco-Innovations.
Dr. Islam Mohamed (Chair)
Dr. Islam Mohamed (Chair), an Honours BSc graduate in Genetics, became a Radiation Oncologist in 2000. At BC Cancer, he has specialized in lung, breast, skin cancers, and sarcoma, with expertise in stereotactic radiation. As a clinical investigator, he has contributed to research, ethics boards, and cancer trial committees. His expertise in cancer genomics, radiobiology, and medical physics now informs his role as an investor and advisor in Canadian biotech firms, including Linax Technologies, IllumiSonics, Asep Medical, and Onco-Innovations.
Dr. Michael Lock
Dr. Michael Lock is a professor at the University of Western Ontario with training in radiation oncology from top institutions. He has led major programs including Radiation Oncology Chair, Medical Director of the London Regional Cancer Program, and provincial advisory roles. A recognized leader in multidisciplinary cancer care, he collaborates globally with the IAEA, UN, and WHO. He also holds management training from Rotman and has received awards like the Human Touch and MAC Administrative Awards.
Dr. Michael Lock
Dr. Michael Lock is a professor at the University of Western Ontario with training in radiation oncology from top institutions. He has led major programs including Radiation Oncology Chair, Medical Director of the London Regional Cancer Program, and provincial advisory roles. A recognized leader in multidisciplinary cancer care, he collaborates globally with the IAEA, UN, and WHO. He also holds management training from Rotman and has received awards like the Human Touch and MAC Administrative Awards.
Dr. Michael Lock
Dr. Michael Lock is a professor at the University of Western Ontario with training in radiation oncology from top institutions. He has led major programs including Radiation Oncology Chair, Medical Director of the London Regional Cancer Program, and provincial advisory roles. A recognized leader in multidisciplinary cancer care, he collaborates globally with the IAEA, UN, and WHO. He also holds management training from Rotman and has received awards like the Human Touch and MAC Administrative Awards.
Dr. Michael Lock
Dr. Michael Lock is a professor at the University of Western Ontario with training in radiation oncology from top institutions. He has led major programs including Radiation Oncology Chair, Medical Director of the London Regional Cancer Program, and provincial advisory roles. A recognized leader in multidisciplinary cancer care, he collaborates globally with the IAEA, UN, and WHO. He also holds management training from Rotman and has received awards like the Human Touch and MAC Administrative Awards.
Acquisition to Lead the Future of Oncology
Acquisition to Lead the Future of Oncology
Acquisition Details
100% Acquisition of Inka Health AI for $3M in Onco common shares
Closed: February 4th, 2025
Strategic Big Pharma Partnerships
Trusted by top pharmaceutical leaders
Scaling global impact through established collaborations
SynoGraph™ AI Integration
Novel AI: Accelerates identification of patient cohorts with highest benefit from personalized treatments.
Aims to enhance drug development timelines and boosts pipeline efficiency. Complimenting Onco's technology and pipeline.
A World-Class Nobel Prize Winning Oncology Team
Global Experts in AI, oncology, and precision medicine
Proven success in partnerships with leading pharma companies
Dr. Paul Arora
Inka Health Co-Founder Dr. Paul Arora is an epidemiologist and the successfully exited founder of Lighthouse Outcomes. With over a decade of senior leadership experience, he has held key positions in global consulting and has contributed extensively to scientific research, authoring more than 50 publications.
Dr. Paul Arora
Inka Health Co-Founder Dr. Paul Arora is an epidemiologist and the successfully exited founder of Lighthouse Outcomes. With over a decade of senior leadership experience, he has held key positions in global consulting and has contributed extensively to scientific research, authoring more than 50 publications.
Dr. Paul Arora
Inka Health Co-Founder Dr. Paul Arora is an epidemiologist and the successfully exited founder of Lighthouse Outcomes. With over a decade of senior leadership experience, he has held key positions in global consulting and has contributed extensively to scientific research, authoring more than 50 publications.
Dr. Paul Arora
Inka Health Co-Founder Dr. Paul Arora is an epidemiologist and the successfully exited founder of Lighthouse Outcomes. With over a decade of senior leadership experience, he has held key positions in global consulting and has contributed extensively to scientific research, authoring more than 50 publications.
Dr. Steve Jones
Dr. Steve Jones is a genomicist and the Director of the Genome Sciences Centre at BC Cancer. A leading expert in genomics and cancer research, he has authored over 500 scientific publications in the field. He is also the founder of Ifowonco Bioinformatics Inc. and Alamya Health, PBC, and holds the prestigious title of Canada Research Chair in Computational Genomics.
Dr. Steve Jones
Dr. Steve Jones is a genomicist and the Director of the Genome Sciences Centre at BC Cancer. A leading expert in genomics and cancer research, he has authored over 500 scientific publications in the field. He is also the founder of Ifowonco Bioinformatics Inc. and Alamya Health, PBC, and holds the prestigious title of Canada Research Chair in Computational Genomics.
Dr. Steve Jones
Dr. Steve Jones is a genomicist and the Director of the Genome Sciences Centre at BC Cancer. A leading expert in genomics and cancer research, he has authored over 500 scientific publications in the field. He is also the founder of Ifowonco Bioinformatics Inc. and Alamya Health, PBC, and holds the prestigious title of Canada Research Chair in Computational Genomics.
Dr. Steve Jones
Dr. Steve Jones is a genomicist and the Director of the Genome Sciences Centre at BC Cancer. A leading expert in genomics and cancer research, he has authored over 500 scientific publications in the field. He is also the founder of Ifowonco Bioinformatics Inc. and Alamya Health, PBC, and holds the prestigious title of Canada Research Chair in Computational Genomics.
Dr. Winson Cheung
Dr. Winson Cheung is a medical oncologist specializing in gastrointestinal cancers and the head of the Oncology Outcomes Research Group. With over 300 scientific publications, he has secured more than $20 million in research funding. He previously served as a member of the CDA Expert Review Committee and as an advisor to Flatiron Health.
Dr. Winson Cheung
Dr. Winson Cheung is a medical oncologist specializing in gastrointestinal cancers and the head of the Oncology Outcomes Research Group. With over 300 scientific publications, he has secured more than $20 million in research funding. He previously served as a member of the CDA Expert Review Committee and as an advisor to Flatiron Health.
Dr. Winson Cheung
Dr. Winson Cheung is a medical oncologist specializing in gastrointestinal cancers and the head of the Oncology Outcomes Research Group. With over 300 scientific publications, he has secured more than $20 million in research funding. He previously served as a member of the CDA Expert Review Committee and as an advisor to Flatiron Health.
Dr. Winson Cheung
Dr. Winson Cheung is a medical oncologist specializing in gastrointestinal cancers and the head of the Oncology Outcomes Research Group. With over 300 scientific publications, he has secured more than $20 million in research funding. He previously served as a member of the CDA Expert Review Committee and as an advisor to Flatiron Health.
Dr. James Orbinski
Dr. James Orbinski is a globally renowned humanitarian, scholar, and scientific advisor. A Nobel Peace Prize recipient on behalf of Médecins Sans Frontières, and Officer of the Order of Canada, he has dedicated his career to global health and humanitarian work. He is the founding director of York University’s Dahdaleh Institute for Global Health Research and previously served as the International Council President of Doctors Without Borders.
Dr. James Orbinski
Dr. James Orbinski is a globally renowned humanitarian, scholar, and scientific advisor. A Nobel Peace Prize recipient on behalf of Médecins Sans Frontières, and Officer of the Order of Canada, he has dedicated his career to global health and humanitarian work. He is the founding director of York University’s Dahdaleh Institute for Global Health Research and previously served as the International Council President of Doctors Without Borders.
Dr. James Orbinski
Dr. James Orbinski is a globally renowned humanitarian, scholar, and scientific advisor. A Nobel Peace Prize recipient on behalf of Médecins Sans Frontières, and Officer of the Order of Canada, he has dedicated his career to global health and humanitarian work. He is the founding director of York University’s Dahdaleh Institute for Global Health Research and previously served as the International Council President of Doctors Without Borders.
Dr. James Orbinski
Dr. James Orbinski is a globally renowned humanitarian, scholar, and scientific advisor. A Nobel Peace Prize recipient on behalf of Médecins Sans Frontières, and Officer of the Order of Canada, he has dedicated his career to global health and humanitarian work. He is the founding director of York University’s Dahdaleh Institute for Global Health Research and previously served as the International Council President of Doctors Without Borders.
Alind Gupta
Alind Gupta is a Co-Founder of Inka Health and an Adjunct Professor at the University of Toronto. He has deep technical expertise in advanced real-world evidence, AI and causal inference methods. He has led advanced analytics projects at a major US consultancy and is a globally referenced author in health technology assessment (HTA) guidance documents.
Alind Gupta
Alind Gupta is a Co-Founder of Inka Health and an Adjunct Professor at the University of Toronto. He has deep technical expertise in advanced real-world evidence, AI and causal inference methods. He has led advanced analytics projects at a major US consultancy and is a globally referenced author in health technology assessment (HTA) guidance documents.
Alind Gupta
Alind Gupta is a Co-Founder of Inka Health and an Adjunct Professor at the University of Toronto. He has deep technical expertise in advanced real-world evidence, AI and causal inference methods. He has led advanced analytics projects at a major US consultancy and is a globally referenced author in health technology assessment (HTA) guidance documents.
Alind Gupta
Alind Gupta is a Co-Founder of Inka Health and an Adjunct Professor at the University of Toronto. He has deep technical expertise in advanced real-world evidence, AI and causal inference methods. He has led advanced analytics projects at a major US consultancy and is a globally referenced author in health technology assessment (HTA) guidance documents.
Reach Us
1309 – 7th Street SW
Calgary, Alberta, Canada
T2R 1A5
investors@oncoinnovations.com
+1 (888) 261–8055
© 2025 Onco-Innovations Limited | All Rights Reserved
Reach Us
1309 – 7th Street SW
Calgary, Alberta, Canada
T2R 1A5
investors@oncoinnovations.com
+1 (888) 261–8055
© 2025 Onco-Innovations Limited | All Rights Reserved
Reach Us
1309 – 7th Street SW
Calgary, Alberta, Canada
T2R 1A5
investors@oncoinnovations.com
+1 (888) 261–8055
© 2025 Onco-Innovations Limited | All Rights Reserved
Reach Us
1309 – 7th Street SW
Calgary, Alberta, Canada
T2R 1A5
investors@oncoinnovations.com
+1 (888) 261–8055
© 2025 Onco-Innovations Limited | All Rights Reserved